Washington has once again found itself at an odd diplomatic crossroads when it comes to India's narcotics record. US President Donald Trump publicly praised Prime Minister Narendra Modi's administration for what he called "historic progress" in combating drug trafficking and disrupting narcoterrorist organisations. Yet simultaneously, India remains on the United States' list of major drugs illicitly producing or trafficking nations — a designation that carries serious policy and trade consequences.
The President's remarks came during a broader address on his administration's anti-drug campaign, in which he highlighted stepped-up enforcement actions against transnational drug cartels and groups he characterised as using narcotics as a weapon of destabilisation. Within that context, he specifically singled out India's cooperation and domestic measures to curb the movement of illegal opiates.
However, the US Drug Enforcement Administration's annual National Drug Threat Assessment has long flagged India as a significant source country for pharmaceutical-grade raw materials and certain opiate derivatives that can be diverted into illicit supply chains. The listing has historically raised concerns among lawmakers in Washington about the adequacy of Indian customs enforcement, border controls, and prosecutorial follow-through on narcoterrorism links attributed to cross-border networks operating from Pakistan-occupied Kashmir and neighbouring routes.
Critics of the listing have argued that India's vast legal poppy cultivation — primarily in Madhya Pradesh, Rajasthan, and Uttar Pradesh for pharmaceutical exports — is sometimes insufficiently monitored, allowing diversion into black markets. India has repeatedly defended its record, pointing to its licensing regime, the Central Bureau of Narcotics, and bilateral information-sharing agreements with American agencies.
The contradiction between public praise and administrative listing has drawn attention from observers who note that while the executive branch may wish to highlight cooperative wins with New Delhi, the technical drug-assessment apparatus within the US government has been reluctant to remove India from the watch list. Diplomatic sources suggest the two governments are aware of the gap and have been discussing ways to align domestic enforcement performance metrics with the removal criteria set by American law.
For now, India occupies an unusual position: applauded by one arm of the US government while being formally scrutinised by another.
